Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Outcome Of The Board Meeting - May 29, 2019

 A.The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 29, 2019, which commenced at 02.30 p.m. and concluded at 09.05 p.m., considered and approved the following: 1.Audited Financial Results for the year ended March 31, 2019. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com 2.Recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2018 - 19 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
29-05-2019
Bigul

Glenmark Pharma gets USFDA nod for antiplatelet drug

 Glenmark Pharmaceuticals on Monday said it has received final approval from the US health regulator for antiplatelet agents Aspirin and extended-rel
27-05-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg
27-05-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Update on board meeting

 The Board Meeting to be held on 29/05/2019 has been revised to 29/05/2019 This is to inform you that the meeting of the Board of Directors of the Company scheduled on Wednesday, 29 May, 2019, will consider, apart from audited financial result and declaration of dividend, also consider the proposal to enable raising of funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency(ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt. Please treat this as the intimation required under Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The above is for your information.
25-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of Earnings Call slated for Thursday, May 30, 2019 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
21-05-2019
Bigul

Glenmark Pharma gets USFDA nod for over-active bladder treatment drug

 The approved product is a generic version of Vesicare tablets of Astellas Pharma US Inc
21-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets,5 mg and 10 mg
21-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Clarification On News Item Appeared In Https://Economictimes.Indiatimes.Com Dated 13Th May, 2019, Titled "Pharma Stocks Bleed As US States File Lawsuit Against Generic Drug Firms"

 This has reference to your above emails seeking clarification on the subject matter. In this regard, we have to inform you that in December 2016, the Attorney General of the State of Connecticut along with the Attorneys'' General of various other U.S. states filed for leave to amend an existing lawsuit in Federal Court to allege that the companies in the US generic drug industry including Glenmark had violated antitrust laws by fixing prices and allocating customers. On 5th June, 2018, leave to file the Amended Complaint was granted in the first State AG Action. The Company has denied all the relevant accusations in the first State AG Action and is vigorously defending the matter. On 10th May, 2019, the Attorney General of the State of Connecticut and Attorneys'' General of various U.S. states filed a second lawsuit in Federal Court with similar allegations. The Second law suit includes some of the parties from the first State AG Action as well as additional parties, and its allegations concern additional products which were not referenced in the first law suit. While the Company is currently reviewing the Second suit, we expect to file papers with the Federal Court in due course denying the accusations. Given the early nature of the matter, the Company does not anticipate material impact of the same.
14-05-2019
Bigul

US pharma scandal: Indian firm Glenmark may face a penalty of up to $873 million

 Severe penalties could be levied on the Indian pharma companies varying from $13 million to $873 million; Glenmark could face the highest penalty, while Aurobindo the least.
14-05-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Wednesday, May 29, 2019, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2019 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 1, 2019 to May 31, 2019 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2019.
14-05-2019
Next Page
Close

Let's Open Free Demat Account